poisar

Stocks · News reference

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Vandana Singh

Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AUPHTEVA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Delveinsight

    Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight

    The lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.

    AZNNVSFATEAUPHGSK
  4. Na

    Teva Releases Q3 2026 Aide Memoire

    Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire document to assist investors ahead of third quarter 2026 results, scheduled for release on November 3, 2026, followed by a conference call at 8:00 a.m. ET. The company is transforming into a leading innovative biopharmaceutical company supported by its generics business.

    TEVA
  5. Na

    Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

    Teva Pharmaceutical Industries announced it will release its Q3 2026 financial results on November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. The company is executing its Pivot to Growth strategy focused on expanding its innovative and biosimilar medicines pipeline while maintaining its generics business.

    TEVA